Business Context and Reporting Period
This Form 6-K filing by Stratasys Ltd. covers the month of September 2013. The report details a significant capital raising event where the company entered into an underwriting agreement on September 12, 2013, with J.P. Morgan Securities LLC as the representative underwriter.
Key Financial Metrics
The filing focuses on the terms of a secondary offering rather than operational financial results for a specific period. Key financial figures related to the transaction include:
- Shares Offered: 4,500,000 ordinary shares.
- Public Offering Price: $93.00 per share.
- Underwriter Purchase Price: $89.745 per share.
- Expected Net Proceeds: Approximately $402.2 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase an additional 675,000 shares at the same price.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the execution of the underwriting agreement for the sale of 4,500,000 shares. The transaction is expected to close on September 18, 2013, subject to customary closing conditions. This represents a substantial increase in the company's equity capital compared to the prior period.
Guidance, Outlook, and Risks
The filing does not contain specific management guidance, outlook, or commentary on future operational performance. The document notes that the Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. It explicitly states that these representations were made solely for the benefit of the parties to the agreement and may be subject to limitations.
Investor Verification Checklist
- Verify the closing of the offering on or around September 18, 2013.
- Confirm the final net proceeds received after all expenses are deducted.
- Check if the underwriters exercised the 30-day over-allotment option for an additional 675,000 shares.
- Review the effective shelf registration statement (Form F-3, File No. 333-190965) for full details on the offering.